
|Articles|July 18, 2019
Management of ocular inflammation and pain using novel insert
Author(s)Julianne Mobilian
ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).
Advertisement
Sydney Tyson, MD, shares the take-home message from the presentation he delivered at the 2019
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
2
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
3
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
4
Study shows significant ocular changes following hemodialysis
5














































